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Abstract
Background: Patients with spinal cord injury (SCI) have a higher prevalence of cardiovascular diseases compared to
the healthy population. Aerobic exercise training is one of the recommended treatments. However, literature regarding
the effect of aerobic training on patients with SCI is scarce. This study evaluated changes in parameters of exercise
physiology and serum myokines immediately after exercise and after a training program among patients with SCI.
Methods: Male patients with SCI and age- and sex-matched healthy individuals were recruited. Cardio-pulmonary
exercise testing (CPET) was used to determine oxygen uptake at peak exercise and anaerobic threshold in both groups.
The patients with SCI attended aerobic exercise training for 36 sessions within 12–16 weeks. Basic data, hemodynamic
and exercise physiology parameters, and serum myokine (myostatin, IGF-1, and follistatin) concentrations were
measured pre- and post-exercise in both groups, and were repeated in patients with SCI post-training.
Results: Eleven patients with SCI underwent CPET and 5 completed the training. The 11 patients and 16 healthy adults
had no differences in baseline serum myokine concentrations before CPET. Immediately after the CPET, the reference
group had an 18 ± 19 % increase in serum IGF-1, while the patients had no observable myokine changes. After aerobic
exercise training, the 5 patients had a 48 ± 18 % increase in serum myostatin compared to the pre-training level,
although the body weight and exercise physiology parameters remained unchanged.
Conclusions: Acute exercise to exhaustion in CPET results in an immediate increase in serum IGF-1 in healthy
individuals while aerobic exercise training results in increased serum myostatin in patients with SCI.
Keywords: Spinal cord injury, Aerobic capacity, Cardio-pulmonary exercise testing, Myostatin, Insulin-like growth factor-1
Background
Over the past decades, advances in medicine and health-
care have greatly decreased risks of respiratory or urinary
tract infection and renal failure in patients with spinal
cord injury (SCI). However, mortality due to cardiovascu-
lar diseases continues to rise [1, 2]. There is a higher
prevalence of cardiovascular diseases in patients with SCI
compared to the healthy population [3, 4] partly because
of decreased physical activity. Muscle weakness and
atrophy, and diminished aerobic capacity are common in
patients with SCI [5], while autonomic dysfunction often
results in altered heart rate (HR) and blood pressure (BP)
response, further heightening cardiovascular risks [6, 7].
Aerobic exercise training is the standard management
for preventing and treating cardiovascular diseases [8]. It
is also one of the essential components of the recom-
mended treatments for patients with SCI [9, 10]. However,
the prescription of exercise training is challenging and
since most patients with SCI lack adequate balance, motor
control, and muscle strength of the lower extremities, arm
ergometry is a frequently used exercise modality.
Recent evidence suggests that myostatin, a strong
inhibitor of muscle hypertrophy counteracting IGF-1, is
also related to aerobic metabolism of muscle [11–16].
IGF-1 is a growth controlling protein that affects the
development of multiple systems, with the musculo-
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skeletal as one of the most important [17–19]. In the
hypothesis of the “accelerator-brake” model [11–14, 20],
IGF-1 provides the initial muscle growth stimulus, and
myostatin increases subsequently to prevent overgrowth
of the muscle. Currently there are limited studies that
explore the changes of serum myokines after chronic
exercise training in patients with SCI. Only one small trial
indicated no significant changes of serum myokines after
activity-based training [21].
The present study aimed to evaluate the training effect
of aerobic exercise using arm ergometry and changes in
serum myokines immediately after exercise and after a
training program in patients with SCI. It was hypothesized
that exercise training might improve aerobic capacity and
muscle strength, and result in elevated myokines.
Methods
Patient eligibility
Patients with SCI visiting the out-patient clinic of the
Department of Physical Medicine and Rehabilitation of
National Taiwan University Hospital were recruited. The
inclusion criteria were age >20 years, male sex, and
onset of injury more than 1 year. The diagnosis was
based on the American Spinal Injury Association (ASIA)
standards. Patients with known heart disease, atrial
fibrillation/flutter, ventricular bigeminy, active inflamma-
tory disease, malignancy, and cardiac pacemakers were
excluded. Those who were unable to perform arm ergo-
metry were further excluded.
For comparison of baseline serum concentration of
myokines, sex- and age-matched healthy volunteers in
the same facility were recruited as the reference group.
We certify that all applicable institutional and govern-
mental regulations concerning the ethical use of human
volunteers were followed during the course of this
research. The hospital’s Research Ethic Committee
approved the study protocol and all of the participants
provided written informed consent.
Experimental protocol
Basic data, including age, height, and weight were
obtained at the time of enrollment. Height was mea-
sured to the nearest 0.1 cm and weight to the nearest
0.1 kg on an electronic scale. The duration from injury
to enrollment, neurologic level, and ASIA impairment
scale (AIS) were recorded for the patients with SCI.
All of the participants underwent CPET. Their HR
and blood BP were monitored throughout the test at rest
and every 30 s. The peak responses of these parameters
during CPET were also recorded. Serum myostatin, IGF-
1, and follistatin concentrations were measured immedi-
ately before and after the CPET.
The patients with SCI were invited to undergo a 12- to
16-week exercise training by arm ergometry. The CPET
and measurements of hemodynamic parameters and
cytokines were repeated after completion of the training.
All the blood samples were taken when the partici-
pants were resting, immediately before and after the
CPET and after the exercise training.
Cardio-pulmonary exercise testing (CPET)
With the patient seated on the arm ergometer (Corival,
Lode B.V., Zernikepark 16, Groningen, Netherlands) and
after 2 min of baseline data collection, there was a 2 min
warm-up arm cranking with no resistance before the load
was increased by 10 W/min in a ramp protocol. Arm
cranking was at 60–70 revolutions per min while the work-
load was gradually increased until volitional exhaustion or
termination according to the guidelines of American Col-
lege of Sports Medicine [22]. The CPET was conducted by
a physiatrist and performed at least two hours after a meal.
During exercise, continuous 12-lead electrocardiogram
and blood pressure (TANGO, SunTech Medical Instru-
ments, NC, USA) were monitored. The expired air was
analyzed by computerized breath-by-breath metabolic
system (Quark b2 system, Cosmed s.r.l., Rome, Italy, or
Cortex MetaMax 3B system, Leipzig, Germany). Exercise
cardio-pulmonary parameters, including workload,
minute ventilation VEð Þ , oxygen uptake VO2ð Þ , carbon
dioxide production VCO2ð Þ , oxygen pulse, ventilator
equivalent for oxygen VE=VO2ð Þ, and ventilatory equiva-
lent for carbon dioxide VE=VCO2ð Þ, were processed.
Two independent observers with experience in CPET
determined the ventilatory threshold. The anaerobic thresh-
old (AT) was based on at least two of the following criteria:
1) VE=VO2 began to increase systematically without a
corresponding increase in VE=VCO2; 2) the end tidal PO2
began to increase without a decrease in the end tidal PCO2;
and 3) departure from linearity for minute ventilation.
Discrepancy in the interpretation AT was solved via discus-
sion. The peak oxygen uptake (peak VO2 ) indicated the
highest VO2 value recorded using CPET and was used as
the main outcome after the training period.
Exercise training by arm ergometry
The exercise training by arm ergometry for the patients
with SCI was 30 min per session, with 3 sessions per
week for 12 weeks. In case of a missed session, the train-
ing duration was prolonged to a maximum of 16 weeks
to complete 36 training sessions. The intensity of train-
ing was guided by CPET results, targeting an intensity of
VO2 at AT throughout the training program. Using a
non-invasive hemodynamic monitoring system (Polar
Electro OY, Finland), HR was monitored throughout the
exercise and the BP every 10 min.
Interval training was adopted, with 1 min of rest between
exercises. The duration of exercise progressed as follows:
one min for the 1st week, 2 min for the 2nd week, 3 min for
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the 3rd and 4th weeks, 6 min for the 5th and 6th weeks,
12 min for the 7th and 8th weeks, 15 min for the 9th and
10th weeks, and 30 min for the 11th and 12th weeks.
ELISA of myostatin, IGF-1, and follistatin
Serum myostatin levels were measured using competi-
tive immunoassay kits according to the manufacturer’s
protocol (Immunodiagnostik AG, Bensheim, Germany).
The full-length myostatin peptide was measured with
high specificity. The test sensitivity was 270 pg/ml, while
the intra- and inter-assay variabilities were <10 and
<15 %, respectively [23, 24].
Serum IGF-1 levels were measured using ELISA kits
(Mediagnost, Reutlingen, Germany). Sensitivity was
0.09 ng/ml and the inter- and intra-assay variability were
6.8 and 6.7 %, respectively [25].
Serum follistatin was analyzed by sandwich ELISA
(QuantikineH, R&D Systems, Minneapolis, MN, USA).
Sensitivity was 29 pg/ml and intra- and inter-assay
variability were 2.4, and 7.1 %, respectively [25].
Statistical analysis
The optical density values versus concentration for the
standard curve were fitted to a four-parameter logistic
regression model. The test of differences between the SCI
and reference groups was performed non-parametrically
using the Mann–Whitney test, while the Wilcoxon
matched pairs test was used to analyze changes in the
parameters before and after exercise, or before and after
training. Statistical significance was set at p < 0.05. Descrip-
tive statistics (mean, standard deviation and coefficient of
variation [CV]) and the statistical tests were performed
using the SPSS® 11.5 (SPSS Inc. Chicago, Illinois, USA).
Results
Basic data
There were 16 patients with SCI recruited. Five were
excluded because of inability perform arm ergometry.
Six patients dropped out during the exercise training
program for personal reasons (Fig. 1), no adverse event
was reported during the training. Table 1 lists the injury
levels and the impairment scales of the patients with
SCI. The mean duration from onset of injury to exercise
test was 13.9 ± 5.0 years.
There were 16 healthy male adults in the reference
group, and no differences existed in age and body weight
and height when compared with the SCI group (Table 2).
There were also no differences in resting serum myokine
concentrations between groups. The reference group
had significantly higher heart rate, work load and oxygen
uptake at peak exercise (Table 2).
Cardio-pulmonary exercise testing (CPET)
Table 2 lists the baseline values and changes of concen-
trations of myokines after CPET. The reference group
had significantly increased IGF-1 after CPET (18 ± 19 %
above baseline, p = 0.001), while myostatin and follistatin
remained unchanged (p = 0.179 and 0.918, respectively).
The serum myokine concentrations in the SCI group
after CPET showed no differences when compared with
the values before CPET (p = 0.594, 0.772, 0.504, for
myostatin, IGF-1, and follistatin, respectively)..
Exercise training by arm ergometry
Five patients with SCI completed the 12–16 weeks of ex-
ercise training. After training, serum myostatin concen-
tration increased by 48 ± 18 %, which was significantly
higher compared to the pre-training status (Table 3).
IGF-1 and follistatin remained unchanged. The increase
in peak VO2 and peak VE were not significant. The body
weight and resting and peak hemodynamic parameters
also remained the same. Two of the five patients did not
reach AT VO2 during CPET due to fatigue.
Discussion
The present study demonstrates that aerobic exercise
training by arm ergometry results in increased serum
myostatin level in patients with chronic SCI, even
though the aerobic capacity and hemodynamic parame-
ters do not change significantly. Acute exercise to ex-
haustion in the CPET leads to an immediate increase in
serum IGF-1 in the reference group.
Myostatin has long been considered a cytokine that
negatively regulates muscle growth. Recent evidence also
point to its role in regulating the energy system of mus-
cles. In the proposed “accelerator-brake” model, myosta-
tin and IGF-1 act as counter-regulatory molecules for
muscle hypertrophy [11–14, 20]. Thus, myostatin
expression theoretically increases to limit the growth sig-
nals of muscle tissue such as exercise or growth factors.
On the other hand, animal studies suggest that myos-
tatin is also related to aerobic capacity. In vitro study
have shown that myostatin deficiency result in muscle
fiber type conversion towards anaerobic metabolism [15,
16]. In vivo, there is also decreased exercise tolerance
and oxygen consumption in myostatin-deficient mice
[26]. Literature regarding responses of serum myostatin
after exercise training in humans are limited and mainly
focused on resistance training [27, 28]. Relevant data is
limited for patients with SCI.
To date, this is the first study to show that aerobic
exercise training by arm ergometry in patients with
chronic SCI leads to elevated serum myostatin concen-
tration. In the hypothesis of the “accelerator-brake”
model [11–14, 20], IGF-1 increases first after exercise as
muscle growth stimulus, followed by myostatin, which
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increases correspondingly to provide negative feedback
signal. Our study failed to show increased IGF-1 after
exercise training which may be due to inadequate exer-
cise intensity, although further evidence is required to
test the hypothesis. On the other hand, the increased
myostatin may indicate an initial change of aerobic
metabolism of muscle after aerobic training, although
there are no detectable peak VO2 changes in CPET.
The present study shows an immediate increase in
serum IGF-1 level after acute exercise to exhaustion in
CPET, but only in healthy participants and not in patients
with SCI. IGF-1 is an age-related serum protein with
growth controlling ability [17]. It affects the development
of multiple systems, with the musculo-skeletal as one of
the most important [18, 19]. Previous trials report an
immediate increase in serum IGF-1 after bouts of exercise
in healthy adults [29–31]. It was hypothesized that IGF-1
is released from skeletal muscle independent of growth
hormone stimulation. The mean percentage of increase
ranges from 13 % to 33 % in different studies [29–31],
while the results here show an average of 18 % increase.
Of note, the increase in IGF-1 is also influenced by exer-
cise intensity [31]. All of the trials used an intensity of ex-
ercise training at or above AT VO2. Part of the reason for
the unresponsiveness of serum IGF-1 level after exercise
in patients with SCI in the present study may be inad-
equate exercise intensity during CPET due to early
fatigue.
There are few related studies available and a recent
trial indicates no change in myostatin and IGF-I, as well
as in body weight, among patients with SCI after chronic
exercise training [21]. In contrast to the aerobic training
by arm ergometry in this study, the cited trial used
activity-based training that mainly consisted of resist-
ance and locomotor training focused on the lower
extremities.
The study had several limitations. Since this study did
not measure the change in skeletal muscle mass or
Fig. 1 Flow diagram of experiment












1 C3 NA C4 C4 D -
2 C5 C5 C5 C5 A -
3 NA T6 T6 T6 A -
4 L1-2 L1 L1 L1 A -
5 C5 C6 C5 C5 B -
6 C4-5 C4 C4 C4 A +
7 L4 L3 L2 L2 D +
8 L1 L1 L1 L1 A +
9 C4-5 C5 C4 C4 A +
10 C5-6 C6 C6 C6 A +
11 NA T1 C5 C5 C +
Abbreviations: AIS the American spinal injury association impairment scale; NA
not applicable
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Table 2 Basic data and change of serum myokines after exercise testing in reference and SCI (pre-training) groups
Reference (n = 16) SCI (n = 11) p valueb
Basic data Age (year) 44.7 ± 6.4 39.9 ± 7.1 0.093
Height (cm) 171.8 ± 4.6 169.7 ± 5.7 0.298
Weight (kg) 71.9 ± 9.9 72.0 ± 11.5 0.786,
BMI (kg/m2) 24.3 ± 2.4 25.0 ± 3.7 0.693
Resting myostatin (ng/ml) 6.1 ± 1.6 6.1 ± 1.8 0.980
IGF-1 (ng/ml) 223.4 ± 62.2 216.4 ± 49.5 0.805
follistatin (ng/ml) 1284.4 ± 809.0 1100.9 ± 354.7 0.587
Change of myokines Δmyostatin (ng/ml) 0.4 ± 1.6 0.3 ± 1.1 0.348
ΔIGF-1 (ng/ml) 40.6 ± 43.0a 2.1 ± 48.3 0.030
Δfollistatin (ng/ml) 59.4 ± 349.7 55.5 ± 498.4 0.657
Peak exercise HR (beat/min) 138.8 ± 13.8 117.4 ± 23.8 0.031
VO2 (ml/min) 1454.5 ± 263.9 877.5 ± 426.2 0.012
VO2 (ml/min/kg) 20.5 ± 4.0 12.3 ± 5.5 0.026
VΕ (ml/min) 63912.5 ± 15181.1 32845.5 ± 15628.5 0.032
Work load (watt) 38.0 ± 31.0 80.0 ± 19.0 0.009
Abbreviations: SCI spinal cord injury, BMI body mass index, IGF-1 insulin-like growth factor-1, HR heart rate, VO2 oxygen uptake, VE minute ventilation
ap < 0.05 by comparison between resting and peak exercise status by Wilcoxon matched pairs test
bComparison between reference and SCI groups by Mann–Whitney test
Table 3 The comparison in the SCI groups before and after 12–16 weeks of training
SCI (n = 5) P valuea
Pre-training Post-training
Basic data Age (year) 39.6 ± 7.4 - -
Height (cm) 167.6 ± 6.0 167.6 ± 6.0 -
Weight (kg) 65.6 ± 6.6 67.9 ± 7.3 0.180
BMI (kg/m2) 23.5 ± 3.4 24.3 ± 3.8 0.180
Resting HR (beat/min) 72.5 ± 13.8 71.8 ± 13.8 0.992
SBP (mmHg) 109.5 ± 24.8 110.6 ± 32.1 0.128
DBP (mmHg) 65.9 ± 11.6 67.4 ± 15.0 0.799
Peak exercise HR (beat/min) 117.4 ± 23.8 120.4 ± 19.7 0.866
SBP (mmHg) 136.8 ± 28.0 145.6 ± 34.1 0.446
DBP (mmHg) 77.8 ± 14.9 78.6 ± 18.5 0.204
VO2 (ml/min) 877.5 ± 426.2 902.4 ± 360.7 0.553
VO2 (ml/min/kg) 12.3 ± 5.5 13.9 ± 5.5 0.866
VΕ (ml/min) 32845.5 ± 15628.5 33580.0 ± 13222.2 0.398
Work load (watt) 39.6 ± 27.9 59.6 ± 32.1 0.312
Myokines myostatin (ng/ml) 6.1 ± 2.0 9.0 ± 1.5 0.018
IGF-1 (ng/ml) 219.7 ± 51.7 204.4 ± 59.6 0.176
follistatin (ng/ml) 1042.7 ± 351.1 909.8 ± 409.0 0.398
Abbreviations: SCI spinal cord injury, BMI body mass index, HR heart rate, SBP systolic blood pressure, DBP diastolic blood pressure, VO2 oxygen uptake, VE, minute
ventilation; IGF-1 insulin-like growth factor-1
aby comparison between pre- and post-training groups using the Wilcoxon matched pairs test
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strength after exercise training, whether increased myos-
tatin reflects a signal of muscle growth or a change in
aerobic metabolism remains unanswered. Some of the
patients with SCI in this study did not attain AT VO2
during CPET due to early limb fatigue, and the true aer-
obic capacity may be underestimated. Similarly, the in-
tensity of training (targeting an intensity of VO2 at AT)
may also be inadequate for most of the patients because
of early limb fatigue. Furthermore, the reference group
did not receive exercise training and as such, there is no
comparison of training effect for patients with SCI. The
limited case number due to difficulty in enrollment
further lessens the discriminative power for the effect of
exercise training. Moreover, there is a substantial hetero-
geneity in the SCI group, with varying severities and
levels of injury, and large inter-individual differences in
serum myokines. Further subgroup analysis is hampered
by the small case number. Nevertheless, the results still
show a marked increase in serum myostatin level after
aerobic exercise training in chronic patients with SCI,
although further studies are warranted to clarify the
interaction between serum myostatin and changes in
aerobic metabolism or muscle growth after training.
Conclusions
This study evaluates the effects of aerobic exercise training
by arm ergometry on serum concentrations of myokines in
patients with chronic SCI. Acute exercise to exhaustion in
CPET results in an immediate increase in serum IGF-1 in
healthy individuals while aerobic exercise training results in
increased serum myostatin in patients with SCI. The inter-
action between serum myostatin and changes in aerobic
metabolism or muscle growth after training requires eluci-
dation by further large-scale prospective studies.
Abbreviations
SCI, spinal cord injury; CPET, Cardio-pulmonary exercise testing; VO2, oxygen
uptake; AT, anaerobic threshold; VCO2, carbon dioxide production; IGF-1,
insulin-like growth factor-1; VE, minute ventilation; HR, heart rate; BP, blood
pressure; ASIA, American Spinal Injury Association
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